A Phase IIIb open label, single arm study of afatinib in EGFR TKI naïve patients with EGFRm+ NSCLC: An interim analysis

Yi-Long Wu,Haiyan Tu,Jifeng Feng,Meiqi Shi,Jun Zhao,Yuyan Wang,Jianhua Chang,Jialei Wang,Ying Cheng,Jing Zhu,Eng-Huat Tan,Kai Li,Yiping Zhang,Victor Lee,Cheng-Ta Yang,Wu-Chou Su,Chi Leung Lam,BJ Srinivasa,Senthil Rajappa,Ching-Liang Ho,Kwok Chi Lam,Yi Hu,Shailesh Arjun Bondarde,Xiaoqing Liu,Jean Fan,David Kuo,Yu Wang,Kaimin Pang,Caicun Zhou

2017-01-01

Abstract:• Study objective: To evaluate the safety of afatinib in patients with locally advanced or metastatic NSCLC harboring EGFR mutation (s) who have never been treated with an EGFR TKI